Abstract | BACKGROUND AND OBJECTIVE: METHODS: RESULTS: A two-compartment model best described the concentration-time data from 30 patients. The mean ± standard deviation parameter estimates were bioavailability (F) of 0.8 ± 0.2, absorption rate constant of 2.4 ± 2 h-1, clearance 2.5 ± 1.1 L/h, central volume of distribution 8.9 ± 3.0 L/h, and transfer rate constraints of 1.8 ± 1.1 h-1 from central to peripheral compartments and 0.7 ± 0.3 h-1 from peripheral to central compartments. For the simulated intermittent dosing regimens, on average, the median trough concentration reduced by 50% for every 40-mL/min/1.73 m2 increase in urinary creatinine clearance. Simulated doses of at least 6 g/day were required for some levels of augmented renal clearance. CONCLUSIONS:
|
Authors | Fekade Bruck Sime, Jason A Roberts, Rosalind L Jeffree, Saurabh Pandey, Santosh Adiraju, Amelia Livermore, Jenie Butler, Suzanne L Parker, Steven C Wallis, Jeffrey Lipman, Menino Osbert Cotta |
Journal | Clinical pharmacokinetics
(Clin Pharmacokinet)
Vol. 60
Issue 5
Pg. 655-664
(05 2021)
ISSN: 1179-1926 [Electronic] Switzerland |
PMID | 33428169
(Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- Levetiracetam
|
Topics |
- Adult
- Anti-Bacterial Agents
(therapeutic use)
- Brain Injuries, Traumatic
(drug therapy)
- Critical Illness
- Humans
- Levetiracetam
- Prospective Studies
- Renal Insufficiency
- Subarachnoid Hemorrhage
(drug therapy)
|